Last reviewed · How we verify
candesartan cilexetil + chlorthalidone + amlodipine
candesartan cilexetil + chlorthalidone + amlodipine is a Antihypertensive combination (ARB + thiazide diuretic + calcium channel blocker) Small molecule drug developed by Hospital Israelita Albert Einstein. It is currently in Phase 3 development for Hypertension (blood pressure control in patients requiring triple-agent therapy).
This triple-combination antihypertensive reduces blood pressure through angiotensin II receptor blockade, thiazide diuresis, and calcium channel inhibition.
This triple-combination antihypertensive reduces blood pressure through angiotensin II receptor blockade, thiazide diuresis, and calcium channel inhibition. Used for Hypertension (blood pressure control in patients requiring triple-agent therapy).
At a glance
| Generic name | candesartan cilexetil + chlorthalidone + amlodipine |
|---|---|
| Sponsor | Hospital Israelita Albert Einstein |
| Drug class | Antihypertensive combination (ARB + thiazide diuretic + calcium channel blocker) |
| Target | Angiotensin II type 1 receptor (AT1R), sodium-chloride cotransporter (NCC), L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Candesartan cilexetil blocks angiotensin II type 1 receptors to reduce vasoconstriction and aldosterone secretion. Chlorthalidone is a thiazide-like diuretic that promotes sodium and water excretion. Amlodipine is a dihydropyridine calcium channel blocker that causes vasodilation. Together, these three agents target complementary pathways to achieve additive blood pressure reduction.
Approved indications
- Hypertension (blood pressure control in patients requiring triple-agent therapy)
Common side effects
- Dizziness
- Hyperkalemia (candesartan component)
- Hypokalemia (chlorthalidone component)
- Peripheral edema (amlodipine component)
- Headache
- Fatigue
Key clinical trials
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (NA)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- candesartan cilexetil + chlorthalidone + amlodipine CI brief — competitive landscape report
- candesartan cilexetil + chlorthalidone + amlodipine updates RSS · CI watch RSS
- Hospital Israelita Albert Einstein portfolio CI
Frequently asked questions about candesartan cilexetil + chlorthalidone + amlodipine
What is candesartan cilexetil + chlorthalidone + amlodipine?
How does candesartan cilexetil + chlorthalidone + amlodipine work?
What is candesartan cilexetil + chlorthalidone + amlodipine used for?
Who makes candesartan cilexetil + chlorthalidone + amlodipine?
What drug class is candesartan cilexetil + chlorthalidone + amlodipine in?
What development phase is candesartan cilexetil + chlorthalidone + amlodipine in?
What are the side effects of candesartan cilexetil + chlorthalidone + amlodipine?
What does candesartan cilexetil + chlorthalidone + amlodipine target?
Related
- Drug class: All Antihypertensive combination (ARB + thiazide diuretic + calcium channel blocker) drugs
- Target: All drugs targeting Angiotensin II type 1 receptor (AT1R), sodium-chloride cotransporter (NCC), L-type calcium channel
- Manufacturer: Hospital Israelita Albert Einstein — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension (blood pressure control in patients requiring triple-agent therapy)
- Compare: candesartan cilexetil + chlorthalidone + amlodipine vs similar drugs
- Pricing: candesartan cilexetil + chlorthalidone + amlodipine cost, discount & access